Analysts Set Expectations for Perspective Therapeutics Q1 Earnings

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Equities researchers at Brookline Capital Markets issued their Q1 2027 earnings estimates for Perspective Therapeutics in a research report issued to clients and investors on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.10) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.14) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 44.22%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million.

CATX has been the subject of several other reports. BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Finally, Piper Sandler dropped their price target on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $12.38.

Perspective Therapeutics Stock Up 2.5%

Shares of CATX opened at $3.26 on Thursday. The firm’s 50 day moving average is $3.08 and its 200-day moving average is $3.94. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently bought and sold shares of CATX. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $28,000. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $31,000. AXQ Capital LP raised its holdings in shares of Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of Perspective Therapeutics in the 4th quarter valued at approximately $35,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.